Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr
Go back to Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr| INSMED (NASDAQ: INSM) | Delayed: 102.15 +3.54 (3.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.61 | 52 Week High | $19.30 | |||
| Open | $98.84 | 52 Week Low | $9.02 | |||
| Day High | $103.15 | P/E | N/A | |||
| Day Low | $97.60 | EPS | $-1.69 | |||
| Volume | 4,199,722 | |||||
